Probiodrug Obtains Core Patent for Alzheimer Treatment in the U.S.
"We are very pleased about this patent as QC inhibition is at the core of our new treatment paradigm in Alzheimer's disease", said Hans-Ulrich Demuth, CSO and co-founder of Probiodrug. "This is the first patent covering a method that has the potential to be a frontline therapy for Alzheimer's disease."
"Probiodrug has a strong intellectual property program with over 160 patent applications for broad coverage of QC inhibitors, including composition of matter, formulations, and methods of treatment claims," says Matthias Hoffmann, VP Operations and Head of Intellectual Property. "These methods of treatment claims add to two U.S. patents issued to Probiodrug in April and May 2008, which cover the first small molecule inhibitors of glutaminyl cyclase."
Most read news
Other news from the department research and development
Get the life science industry in your inbox
From now on, don't miss a thing: Our newsletter for biotechnology, pharma and life sciences brings you up to date every Tuesday and Thursday. The latest industry news, product highlights and innovations - compact and easy to understand in your inbox. Researched by us so you don't have to.